ClinicalTrials.gg
CompletedNCT02611778COLUMBUS-AMDUpdated Sep 30, 2021Results posted

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration

A Phase 3 interventional study of ranibizumab in Age-related Macular Degeneration (AMD), sponsored by Bioeq GmbH. Completed at 58 sites in 12 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-09-30.

Sponsored by Bioeq GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
712
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
8th of 124
712 · median 64
Started
2015
with 6 others
Phase 3
31 of 125
2 open now
Registered
104th of 125
by date

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 8th largest by enrollment of the 124 interventional ones that give a count, is one of 7 that started in 2015, is one of 31 in phase 3, and was the 104th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration.

03

Conditions studied

  • Age-related Macular Degeneration (AMD)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years of either gender
  • Signed form must be obtained before any study-related procedure is performed
  • Willingness and ability to undertake all scheduled visits and assessments
  • Women must be or surgically sterile
  • Newly diagnosed, angiographically documented, primary active Choroidal Neovascularization (CNV) lesion secondary to age-related macular degeneration (AMD)
  • Sufficiently clear ocular media and adequate pupillary dilation to permit good quality ocular imaging
  • Best-corrected Visual Acuity (BCVA) in the study eye, determined by standardized Early Treatment Diabetic Retinopathy Study (ETDRS) testing, between 20/32 (0.63) and 20/100 (0.2) Snellen equivalent
  • Foveal Center Point (FCP) retinal thickness in at Screening ≥ 350 µm
  • BCVA in the fellow eye, determined by standardized ETDRS testing, at least 20/100 (0.2) Snellen equivalent

Exclusion criteria

Exclusion criteria:

  • Employees of clinical study sites, individuals directly involved with the conduct of the study or immediate family members thereof, prisoners, and persons who are legally institutionalized
  • Any previous treatment with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) agent in either eye
  • History of vitrectomy, macular surgery or other surgical intervention for AMD in the study eye
  • History of IVT or periocular injections of or device implantation within six months prior to Screening in the study eye
  • Prior treatment with verteporfin (photodynamic therapy), transpupillary thermotherapy, radiation therapy, or retinal laser treatment (e.g. focal laser photocoagulation) in the study eye
  • Topical ocular corticosteroids administered for at least 30 consecutive days within three months prior to Screening
  • Any other intraocular surgery (including cataract surgery) in the study eye within three months prior to Screening
  • Sub- or intra-retinal hemorrhage that comprises more than 50% of the entire lesion in the study eye
  • Fibrosis or atrophy involving the center of the fovea or influencing central visual function in the study eye
  • CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia
  • Retinal pigment epithelial tear involving the macula in the study eye
  • History of full-thickness macular hole in the study eye
  • History of retinal detachment in the study eye
  • Current vitreous hemorrhage in the study eye
  • Spherical equivalent of the refractive error in the study eye demonstrating more than 8 diopters of myopia
  • For patients who have undergone prior refractive or cataract surgery in the study eye, the preoperative refractive error in the study eye cannot exceed 8 diopters of myopia
  • History of corneal transplant in the study eye
  • Aphakia in the study eye. Absence of an intact posterior capsule is allowed if it occurred as a result of Yttrium-Aluminium-Garnet (YAG) laser posterior capsulotomy in association with prior posterior chamber intraocular lens (IOL) implantation
  • Active or recent (within 4 weeks) intraocular inflammation of clinical significance in the study eye such as active infections of the anterior segment (excluding mild blepharitis) including conjunctivitis, keratitis, scleritis, uveitis or endophthalmitis
  • Uncontrolled hypertension or glaucoma in the study eye (defined as intraocular pressure (IOP) ≥30 mm Hg, despite treatment with anti-glaucomatous medication)
  • Ocular disorders in the study eye (i.e. retinal detachment, pre-retinal membrane of the macula or cataract with significant impact on visual acuity) at the time of enrollment that may confound interpretation of study results and compromise visual acuity
  • Any concurrent intraocular condition in the study eye (e.g. glaucoma, cataract or diabetic retinopathy) that, in the opinion of the Investigator, would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results.
  • Use of other drugs (excluding vitamins, minerals) within 30 days or 5 half-lives from Screening, whichever is longer
  • Any type of advanced, severe or unstable disease, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk
  • Stroke or myocardial infarction within three months prior to Screening
  • Presence of uncontrolled systolic blood pressure > 160 mmHg or uncontrolled diastolic blood pressure > 100 mmHg
  • Known to the investigational drug (ranibizumab or any component of the ranibizumab formulation) or to drugs of similar chemical class or to fluorescein or any other component of fluorescein formulation
  • Current or planned use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine (Plaquenil®), tamoxifen, phenothiazines and ethambutol
  • History of recurrent significant infections and/or current treatment for active systemic infection
  • Pregnancy or lactation
  • Systemic treatment with high doses of corticosteroids (administration of >10 mg/day of prednisolone equivalent) during the last six months prior to Screening
  • Inability to comply with study or follow-up procedures
  • Any diagnosis and/or signs of nAMD requiring treatment with an IVT anti-VEGF agent (e.g. aflibercept, bevacizumab, ranibizumab) within the screening period or at study treatment initiation (Visit 1) in the fellow eye
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
712 participants (actual)

Study arms

  • Experimental
    FYB201

    FYB201 is provided as single use vials and will be administered by intra-vitreal injection.

    Biological: ranibizumab

  • Active comparator
    Lucentis

    Lucentis® is provided as single use vials and will be administered by intra-vitreal injection.

    Biological: ranibizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks

    The primary endpoint was the absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 2 months (8 weeks) of treatment.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 24 Weeks

    Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 24 weeks of treatment.

    Time frame: Baseline and Week 24

  2. Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 48 Weeks

    Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 48 weeks of treatment.

    Time frame: Baseline and Week 48

  3. Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 12 Months

    Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 12 months, calculated as the average of the changes from baseline to Week 40, to Week 44 and to Week 48.

    Time frame: Baseline and 12 Months

  4. Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 24

    Absolute change in Foveal Centre Point (FCP) retinal thickness \[µm\] from baseline to Week 24

    Time frame: Baseline and Week 24

  5. Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 48

    Absolute change in Foveal Centre Point (FCP) retinal thickness \[µm\] from baseline to Week 48

    Time frame: Baseline and Week 48

  6. Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 24

    Absolute change in Foveal Central Subfield (FCS) retinal thickness \[µm\] from baseline to Week 24

    Time frame: Baseline and Week 24

  7. Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 48

    Absolute change in Foveal Central Subfield (FCS) retinal thickness \[µm\] from baseline to Week 48

    Time frame: Baseline and Week 48

  8. Change in Total Lesion Area From Baseline to Week 24

    Absolute change in total lesion area \[mm²\] from baseline to Week 24

    Time frame: Baseline and Week 24

  9. Change in Total Lesion Area From Baseline to Week 48

    Absolute change in total lesion area \[mm²\] from baseline to Week 48

    Time frame: Baseline and Week 48

  10. Change in NEI VFQ-25 Composite Score From Baseline to Week 24

    Absolute change from baseline to Week 24 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score. The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.

    Time frame: Baseline and Week 24

  11. Change in NEI VFQ-25 Composite Score From Baseline to Week 48

    Absolute change from baseline to Week 48 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score. The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.

    Time frame: Baseline and Week 48

  12. Active CNV Leakage at Week 24

    Number and percentage of patients with active CNV leakage at Week 24

    Time frame: Baseline and Week 24

  13. Active CNV Leakage at Week 48

    Number and percentage of patients with active CNV leakage at Week 48

    Time frame: Baseline and Week 48

  14. Fluid-free Macula at Each Visit

    Number and percentage of patients with fluid-free macula at each visit

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48

  15. Anti-drug Antibodies by Scheduled eCRF Visit

    Frequency of patients with anti-drug antibodies (ADAs) by scheduled eCRF visit

    Time frame: Baseline and Weeks 1, 4, 12, 24, 48

  16. Anti-drug Antibodies Pre- and Post-first Dosing

    Number and percentage of patients with detection of anti-drug antibodies (ADAs) pre-first dosing and post-first dosing (combination of all ADA assessments after first injection of study medication).

    Time frame: Baseline and up to Week 48

07

Results

Posted Sep 30, 2021

Participant flow

Participant flow — Overall Study
MilestoneFYB201Lucentis
Started238239
Completed226226
Not completed1213
Withdrew: Withdrawal by subject28
Withdrew: Adverse event12
Withdrew: Death21
Withdrew: Protocol violation10
Withdrew: Lost to follow-up31
Withdrew: Need for alternative treatment10
Withdrew: Other reason21

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks

The primary endpoint was the absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 2 months (8 weeks) of treatment.

Time frame:
Baseline and Week 8
Reported as:
Mean · letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks
lettersFYB201LucentisTotal
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks5.1 ± 7.525.6 ± 8.635.4 ± 8.10
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: -0.4 · 90% CI -1.6 to 0.9An ANCOVA model was used for the analysis with the change in BCVA between baseline and Week 8 as the dependent variable, the baseline BCVA as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 24 Weeks

Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 24 weeks of treatment.

Time frame:
Baseline and Week 24
Reported as:
Mean · letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 24 Weeks
lettersFYB201LucentisTotal
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 24 Weeks6.9 ± 10.127.1 ± 10.427.0 ± 10.26
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: -0.0 · 90% CI -1.6 to 1.5An ANCOVA model was used for the analysis with the change in BCVA between baseline and Week 24 as the dependent variable, the baseline BCVA as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 48 Weeks

Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 48 weeks of treatment.

Time frame:
Baseline and Week 48
Reported as:
Mean · letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 48 Weeks
lettersFYB201LucentisTotal
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 48 Weeks7.8 ± 11.678.0 ± 11.317.9 ± 11.48
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: -0.1 · 90% CI -1.8 to 1.7An ANCOVA model was used for the analysis with the change in BCVA between baseline and Week 48 as the dependent variable, the baseline BCVA as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 12 Months

Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 12 months, calculated as the average of the changes from baseline to Week 40, to Week 44 and to Week 48.

Time frame:
Baseline and 12 Months
Reported as:
Mean · letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 12 Months
lettersFYB201LucentisTotal
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 12 Months7.8 ± 11.197.9 ± 11.017.8 ± 11.09
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: 0.1 · 90% CI -1.6 to 1.8An ANCOVA model was used for the analysis with the change in BCVA between baseline and 12 months (average of Weeks 40, 44 and 48) as the dependent variable, the baseline BCVA as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 24

Absolute change in Foveal Centre Point (FCP) retinal thickness \[µm\] from baseline to Week 24

Time frame:
Baseline and Week 24
Reported as:
Mean · µm
Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 24
µmFYB201LucentisTotal
Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 24-203.94 ± 147.104-205.45 ± 147.199-204.70 ± 146.986
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: 0.69 · 90% CI -18.22 to 19.60An ANCOVA model was used for the analysis with the change in FCP retinal thickness between baseline and Week 24 as the dependent variable, the baseline FCP retinal thickness as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 48

Absolute change in Foveal Centre Point (FCP) retinal thickness \[µm\] from baseline to Week 48

Time frame:
Baseline and Week 48
Reported as:
Mean · µm
Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 48
µmFYB201LucentisTotal
Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 48-213.26 ± 161.323-211.02 ± 151.950-212.14 ± 156.521
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: 2.68 · 90% CI -16.49 to 21.85An ANCOVA model was used for the analysis with the change in FCP retinal thickness between baseline and Week 48 as the dependent variable, the baseline FCP retinal thickness as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 24

Absolute change in Foveal Central Subfield (FCS) retinal thickness \[µm\] from baseline to Week 24

Time frame:
Baseline and Week 24
Reported as:
Mean · µm
Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 24
µmFYB201LucentisTotal
Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 24-180.37 ± 128.522-181.63 ± 126.466-181.02 ± 127.330
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: -5.91 · 90% CI -22.62 to 10.80An ANCOVA model was used for the analysis with the change in FCS retinal thickness between baseline and Week 24 as the dependent variable, the baseline FCS retinal thickness as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 48

Absolute change in Foveal Central Subfield (FCS) retinal thickness \[µm\] from baseline to Week 48

Time frame:
Baseline and Week 48
Reported as:
Mean · µm
Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 48
µmFYB201LucentisTotal
Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 48-182.85 ± 134.588-190.75 ± 128.691-186.86 ± 131.532
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: 3.68 · 90% CI -13.28 to 20.63An ANCOVA model was used for the analysis with the change in FCS retinal thickness between baseline and Week 48 as the dependent variable, the baseline FCS retinal thickness as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange in Total Lesion Area From Baseline to Week 24

Absolute change in total lesion area \[mm²\] from baseline to Week 24

Time frame:
Baseline and Week 24
Reported as:
Mean · mm²
Change in Total Lesion Area From Baseline to Week 24
mm²FYB201LucentisTotal
Change in Total Lesion Area From Baseline to Week 24-0.5742 ± 4.79222-0.7113 ± 5.35854-0.6418 ± 5.07361
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: 0.070 · 90% CI -0.706 to 0.846An ANCOVA model was used for the analysis with the change in total lesion area between baseline and Week 24 as the dependent variable, the baseline total lesion area as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange in Total Lesion Area From Baseline to Week 48

Absolute change in total lesion area \[mm²\] from baseline to Week 48

Time frame:
Baseline and Week 48
Reported as:
Mean · mm²
Change in Total Lesion Area From Baseline to Week 48
mm²FYB201LucentisTotal
Change in Total Lesion Area From Baseline to Week 48-0.6382 ± 4.81194-1.1814 ± 5.42770-0.9123 ± 5.13128
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: 0.342 · 90% CI -0.547 to 1.230An ANCOVA model was used for the analysis with the change in total lesion area between baseline and Week 48 as the dependent variable, the baseline total lesion area as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange in NEI VFQ-25 Composite Score From Baseline to Week 24

Absolute change from baseline to Week 24 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score. The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.

Time frame:
Baseline and Week 24
Reported as:
Mean · score on a scale
Change in NEI VFQ-25 Composite Score From Baseline to Week 24
score on a scaleFYB201LucentisTotal
Change in NEI VFQ-25 Composite Score From Baseline to Week 243.59 ± 9.6323.55 ± 11.2373.57 ± 10.457
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: 0.21 · 90% CI -1.25 to 1.67An ANCOVA model was used for the analysis with change in NEI VFQ-25 composite score between baseline and Week 24 as dependent variable, baseline NEI VFQ-25 composite score as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryChange in NEI VFQ-25 Composite Score From Baseline to Week 48

Absolute change from baseline to Week 48 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score. The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.

Time frame:
Baseline and Week 48
Reported as:
Mean · score on a scale
Change in NEI VFQ-25 Composite Score From Baseline to Week 48
score on a scaleFYB201LucentisTotal
Change in NEI VFQ-25 Composite Score From Baseline to Week 485.30 ± 12.2053.75 ± 13.1904.53 ± 12.714
Statistical analysis
  • FYB201 vs Lucentis · ANCOVA · Difference in least square means: 1.73 · 90% CI 0.04 to 3.42An ANCOVA model was used for the analysis with change in NEI VFQ-25 composite score between baseline and Week 48 as dependent variable, baseline NEI VFQ-25 composite score as covariate, and (pooled) country and treatment group as fixed effects.
SecondaryActive CNV Leakage at Week 24

Number and percentage of patients with active CNV leakage at Week 24

Time frame:
Baseline and Week 24
Reported as:
Count of participants · Participants
Active CNV Leakage at Week 24
ParticipantsFYB201LucentisTotal
CNV leakage115111226
No CNV leakage106108214
SecondaryActive CNV Leakage at Week 48

Number and percentage of patients with active CNV leakage at Week 48

Time frame:
Baseline and Week 48
Reported as:
Count of participants · Participants
Active CNV Leakage at Week 48
ParticipantsFYB201LucentisTotal
CNV leakage119115234
No CNV leakage9281173
SecondaryFluid-free Macula at Each Visit

Number and percentage of patients with fluid-free macula at each visit

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48
Reported as:
Count of participants · Participants
Fluid-free Macula at Each Visit
ParticipantsFYB201LucentisTotal
Baseline — Fluid-free macula022
Baseline — No fluid-free macula236234470
Week 4 — Fluid-free macula433881
Week 4 — No fluid-free macula187188375
Week 8 — Fluid-free macula6962131
Week 8 — No fluid-free macula154168322
Week 12 — Fluid-free macula8676162
Week 12 — No fluid-free macula141155296
Week 16 — Fluid-free macula8787174
Week 16 — No fluid-free macula136149285
Week 20 — Fluid-free macula8097177
Week 20 — No fluid-free macula146137283
Week 24 — Fluid-free macula86100186
Week 24 — No fluid-free macula141131272
Week 28 — Fluid-free macula8698184
Week 28 — No fluid-free macula140121261
Week 32 — Fluid-free macula9196187
Week 32 — No fluid-free macula131125256
Week 36 — Fluid-free macula8399182
Week 36 — No fluid-free macula142119261
Week 40 — Fluid-free macula87102189
Week 40 — No fluid-free macula133115248
Week 44 — Fluid-free macula92104196
Week 44 — No fluid-free macula129116245
Week 48 — Fluid-free macula105108213
Week 48 — No fluid-free macula120113233
SecondaryAnti-drug Antibodies by Scheduled eCRF Visit

Frequency of patients with anti-drug antibodies (ADAs) by scheduled eCRF visit

Time frame:
Baseline and Weeks 1, 4, 12, 24, 48
Reported as:
Count of participants · Participants
Anti-drug Antibodies by Scheduled eCRF Visit
ParticipantsFYB201LucentisTotal
Baseline — Positive anti-drug antibodies055
Baseline — Negative anti-drug antibodies234233467
Week 1 — Positive anti-drug antibodies000
Week 1 — Negative anti-drug antibodies282957
Week 4 — Positive anti-drug antibodies224
Week 4 — Negative anti-drug antibodies224226450
Week 12 — Positive anti-drug antibodies123
Week 12 — Negative anti-drug antibodies225224449
Week 24 — Positive anti-drug antibodies6612
Week 24 — Negative anti-drug antibodies219219438
Week 48 — Positive anti-drug antibodies91221
Week 48 — Negative anti-drug antibodies220213433
SecondaryAnti-drug Antibodies Pre- and Post-first Dosing

Number and percentage of patients with detection of anti-drug antibodies (ADAs) pre-first dosing and post-first dosing (combination of all ADA assessments after first injection of study medication).

Time frame:
Baseline and up to Week 48
Reported as:
Count of participants · Participants
Anti-drug Antibodies Pre- and Post-first Dosing
ParticipantsFYB201LucentisTotal
Pre-first dosing — Positive anti-drug antibodies055
Pre-first dosing — Negative anti-drug antibodies232231463
Post-first dosing — Positive anti-drug antibodies141428
Post-first dosing — Negative anti-drug antibodies223224447

Adverse events

Collected over From first treatment up to Week 48. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FYB2012/238 (0.8%)19/238 (8%)149/238 (62.6%)
Lucentis1/239 (0.4%)32/239 (13.4%)161/239 (67.4%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventFYB201Lucentis
Atrial fibrillationCardiac disorders3/2381/239
Acute kidney injuryRenal and urinary disorders2/2380/239
Myocardial infarctionCardiac disorders1/2382/239
CataractEye disorders0/2382/239
EndophthalmitisInfections and infestations1/2382/239
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/2382/239
OsteoarthritisMusculoskeletal and connective tissue disorders0/2382/239
Respiratory failureRespiratory, thoracic and mediastinal disorders1/2382/239
Anaemia macrocyticBlood and lymphatic system disorders1/2380/239
Atrial flutterCardiac disorders1/2380/239
Most frequent other events
Showing 10 of 32
Most frequent other events
EventFYB201Lucentis
Neovascular age-related macular degenerationEye disorders19/23822/239
Conjunctival haemorrhageEye disorders14/23819/239
NasopharyngitisInfections and infestations12/23816/239
HypertensionVascular disorders3/23814/239
Punctate keratitisEye disorders8/23812/239
Intraocular pressure increasedInvestigations11/23812/239
Visual acuity reducedEye disorders6/23811/239
C-reactive protein increasedInvestigations10/2385/239
CataractEye disorders1/23810/239
Eye painEye disorders9/2386/239

Baseline characteristics

Safety Set (SAF): The safety set comprised all patients who had received at least one injection with investigational medicinal product.

Age, Continuous
Age, Continuous(years)FYB201LucentisTotal
Mean74.9 ± 8.2676.1 ± 7.8475.5 ± 8.07
Sex: Female, Male
Sex: Female, Male(Participants)FYB201LucentisTotal
Female135134269
Male103105208
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FYB201LucentisTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American000
White236233469
More than one race000
Unknown or Not Reported246
08

Study locations

58 sites
  • Research Site
    Vienna, Austria
  • Research Site
    Brno, Czechia
  • Research Site
    Ostrava, Czechia
  • Research Site
    Plzen, Czechia
  • Research Site
    Praha, Czechia
  • Research Site
    Zlín, Czechia
  • Research Site
    Dijon, France
  • Research Site
    Lyon, France
  • Research Site
    Nantes, France
  • Research Site
    Paris, France
  • University of Bonn, Department of Ophthalmology
    Bonn, Germany
  • Research Site
    Dresden, Germany
  • Research Site
    Freiburg, Germany
  • Research Site
    Göttingen, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Leipzig, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Tuebingen, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Nyíregyháza, Hungary
  • Research Site
    Pécs, Hungary
  • Research Site
    Szeged, Hungary
  • Research Site
    Zalaegerszeg, Hungary
  • Research Site
    Be'er Sheva, Israel
  • Research Site
    Haifa, Israel
  • Research Site
    Jerusalem, Israel
  • Research Site
    Kfar Saba, Israel
  • Research Site
    Petach Tikva, Israel
  • Research Site
    Ramat Gan, Israel
  • Research Site
    Reẖovot, Israel
  • Research Site
    Tel Aviv, Israel
  • Research Site
    Zrifin, Israel
  • Research Site
    Bologna, Italy
  • Research Site
    Chieti, Italy
  • Research Site
    Milano, Italy
  • Research Site
    Pisa, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Torino, Italy
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Rzeszów, Poland
  • Research Site
    Tarnowskie Góry, Poland
  • Research Site
    Tarnów, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Łódź, Poland
  • Research Site
    Kazan, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    Saint Petersburg, Russian Federation
  • Research Site
    Barcelona, Spain
  • Research Site
    Valencia, Spain
  • Research Site
    Zaragoza, Spain
  • Research Site
    Kyiv, Ukraine
  • Research Site
    Odesa, Ukraine
  • Research Site
    Bradford, United Kingdom
  • Research Site
    Bristol, United Kingdom
  • Research Site
    Camberley, United Kingdom
  • Research Site
    London, United Kingdom
  • Research Site
    Rugby, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Dec 2017, 24 months.

Results were first posted in Sep 2021, 3 years 9 months after primary completion.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 24 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2015
First posted
Nov 23, 2015
StartActual
Dec 19, 2015
Primary completionActual
Dec 2017
CompletionActual
Jun 6, 2018
Results first posted
Sep 30, 2021
Last update
Sep 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02611778
Lead sponsor
Bioeq GmbH
Responsible party
Sponsor
First posted
Nov 23, 2015
Start date
Dec 19, 2015
Primary completion
Dec 2017
Completion
Jun 6, 2018
Results posted
Sep 30, 2021
Last update
Sep 30, 2021

Study contacts

Frank G. Holz, Prof. Dr.
principal investigator · University of Bonn, Department of Ophthalmology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion